Pharmacological Differences of Glitazones. Does Peroxisome Proliferator-Activated Receptor-α Activation Make the Difference?**Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.

Journal of the American College of Cardiology

Volumn 52, Issue 10, 2008, Pages 882-884

  Kintscher, Ulrich ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLITAZONE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; RETINOID X RECEPTOR ALPHA; ROSIGLITAZONE; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOCYTE; ANTIINFLAMMATORY ACTIVITY; ATHEROGENESIS; DIABETES MELLITUS; DIABETIC PATIENT; DRUG MECHANISM; DYSLIPIDEMIA; EDITORIAL; GENE TARGETING; HEART INFARCTION; HUMAN; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; RECEPTOR UPREGULATION;

DIABETES MELLITUS, TYPE 2; ENDOTHELINS; HUMANS; INFLAMMATION; PPAR ALPHA; PPAR GAMMA; THIAZOLIDINEDIONES; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

EID: 49849083531     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2008.06.012     Document Type: Editorial

References (10)

1. Staels B., and Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 54 (2005) 2460-2470
2. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
3. Nissen S.E., and Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356 (2007) 2457-2471
4. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
5. Goldberg R.B., Kendall D.M., Deeg M.A., et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia. Diabetes Care 28 (2005) 1547-1554
6. Orasanu G., Ziouzenkova O., Devchand P.R., et al. The peroxisome proliferator-activated receptor-γ agonist pioglitazone represses inflammation in a peroxisome proliferator-activated receptor-α-dependent manner in vitro and in vivo in mice. J Am Coll Cardiol 52 (2008) 869-881
7. Sakamoto J., Kimura H., Moriyama S., et al. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 278 (2000) 704-711
8. Guan H.P., Ishizuka T., Chui P.C., Lehrke M., and Lazar M.A. Corepressors selectively control the transcriptional activity of PPARγ in adipocytes. Genes Dev 28 (2005) 28
9. Glass C.K. Going nuclear in metabolic and cardiovascular disease. J Clin Invest 116 (2006) 556-560
10. Hsiao A., Worrall D.S., Olefsky J.M., and Subramaniam S. Variance-modeled posterior inference of microarray data: detecting gene-expression changes in 3T3-L1 adipocytes. Bioinformatics 20 (2004) 3108-3127